GenScript Biotech Achieves AA MSCI ESG Rating, Recognized as Global Leader in Sustainability

GenScript Biotech's MSCI ESG Rating has been upgraded to AA from A, recognizing the company's excellence in product safety, human capital development, and environment and governance practices. The AA rating is a testament to GenScript's commitment to sustainability in the biotech industry. GenScript has been recognized globally for its sustainability initiatives, including its participation in the United Nations Global Compact and its inclusion in the FTSE4Good Index Series.

GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, has seen its MSCI ESG rating upgraded to AA from A. This upgrade, announced on July 31, 2025, recognizes the company's excellence in product safety and quality, human capital development, and continuous improvement in environment and governance practices [1].

MSCI, one of the world's largest index providers, evaluates global public and private companies on a scale from CCC (laggard) to AAA (leader), according to exposure to industry-specific ESG risks and the ability to manage those risks relative to peers. The AA rating underscores GenScript's strong commitment to sustainability in the biotech industry, placing it among the global leaders in ESG performance [1].

Sherry Shao, Rotating CEO of GenScript Biotech, emphasized the significance of the AA rating, stating, "The AA rating from a globally recognized index is a testament to GenScript's ESG performance. Embedding sustainability into our core business not only enhances our operational resilience but also creates long-term value for our investors and stakeholders worldwide." The company's mission to "Make People and Nature Healthier Through Biotechnology" is reflected in its ESG initiatives [1].

GenScript's ESG leadership is further demonstrated by its participation in the United Nations Global Compact and its inclusion in the FTSE4Good Index Series. Additionally, the company has achieved a Silver Medal from EcoVadis and a "Low Risk" ESG rating from Morningstar Sustainalytics, and its carbon reduction targets have been validated by the Science Based Targets initiative (SBTi) [1].

The upgrade in GenScript's MSCI ESG rating comes amidst a global recognition of its sustainability initiatives. The company's commitment to responsible business practices and sustainable value chains is evident in its partnerships and achievements, such as its Silver Medal from EcoVadis and its inclusion in the FTSE4Good Index Series [1].

GenScript's success in ESG ratings reflects its dedication to sustainability, which is integral to its core business operations and long-term strategy. As the company continues to push the boundaries of sustainable growth in the biotech industry, investors and stakeholders can expect further advancements in ESG performance and long-term value creation.

References:
[1] https://www.prnewswire.com/news-releases/genscript-biotechs-msci-esg-rating-upgraded-to-aa-recognized-as-a-global-leader-302519342.html